Re­gen­eron makes a block­buster case for its PhI­II drug pipeline

While Bio­gen is strug­gling to get its pipeline to per­form, Re­gen­eron ex­ecs put on a demon­stra­tion to­day on how a biotech com­pa­ny with a sec­ond-tier R&D bud­get can per­form bet­ter on the late-stage front than much big­ger com­pa­nies spend­ing much more on re­search. And it led off with bull­ish re­marks on a pair of would-be block­busters, in­clud­ing their top Phase III drug dupilum­ab.

Dur­ing their sec­ond quar­ter re­view, the ex­ec­u­tive team not­ed:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER